Navigation Links
GBS/CIDP Foundation to Hold 10th International Symposium
Date:10/7/2008

Over 250 medical professionals, patients and caregivers from around the

world expected to attend

NARBERTH, Pa., Oct. 7 /PRNewswire/ -- The GBS/CIDP Foundation International will host its tenth international symposium on Guillain-Barre Syndrome (GBS) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Bloomingdale, IL on November 7-9, 2008. Over 250 medical professionals, current and former patients and caregivers from all over the world are expected to attend the three-day event at the Indian Lake Resort.

In addition to general sessions covering the latest developments in current research, diagnosis, treatment and therapies for GBS & CIDP, there will be over twenty workshops offering practical information for patients, caregivers and their physicians. Topics include patient management and long-term outcomes for GBS, CIDP and variants, fatigue, pain and emotional issues, reimbursement and disability, and special sessions for rehabilitation and wheelchair patients.

Speakers and presenters include prominent neurologists who actively treat GBS and CIDP patients and conduct vital research, leading physicians in rehabilitation medicine and physicians who themselves have had the disorder. The symposium will provide invaluable information and networking opportunities for patients, relatives and caregivers who have experienced or had to deal with these rare and potentially catastrophic disorders.

GBS is an inflammatory disorder of the peripheral nerves and is characterized by the rapid onset of weakness and often paralysis of the legs, arms, breathing muscles and face. GBS can develop in persons of any age. CIDP is a rare disorder of the peripheral nerves with weakness occurring over two or more months and is characterized by gradually increasing weakness of the legs and, to a lesser extent, the arms. It is caused by damage to the covering of the nerves, called myelin.

The Foundation was founded
'/>"/>

SOURCE The GBS/CIDP Foundation International
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis
2. More Than 230 Cyclists to Ride in Amgen California Coast Classic Bike Tour to Raise $1.3 Million for Arthritis Foundation
3. International Atomic Energy Agency and National Foundation for Cancer Research Launch Major Initiative to Improve Cancer Prevention and Treatments in Developing Countries
4. Melanoma Research Foundation and Seattle Cancer Care Alliance Host Educational Symposium and Reception for Melanoma Patients, Family Members and Healthcare Providers
5. Foundation for Biomedical Research Board Chairman Awarded Congressional Gold Medal
6. The Parkinsons Disease Foundation Commemorates its 50th Anniversary with Special Scientific Symposium on Parkinsons Disease
7. Rutgers physicist earns prestigious Packard Foundation Science and Engineering Fellowship
8. Agendia BV Announces That its Chief Research Officer Laura van t Veer has Received a 2007 Breast Cancer Research Foundation Award
9. John Timberlake, Valeritas Executive Vice President and General Manager, Named Executive of the Year by the Diabetes Foundation
10. Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
11. eHealth Initiative Foundation Launches Collaborative Research Effort to Improve Drug Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... ... The 2015 Market Research Report on the Global Propanol Industry is ... with a focus on the Chinese situation. Major companies included in the propanol market ... Royal Dutch Shell, LG Chem and Zhejiang Xinhua Chemical. , The report provides a ...
(Date:7/30/2015)... ... July 30, 2015 , ... Leading regenerative veterinary medicine company, ... canine osteoarthritis stem cell product, currently under development for FDA approval. The product ... marketed in the US by Aratana. This product, termed AT-016, is an allogeneic ...
(Date:7/30/2015)... , Inc. (NASDAQ: SNMX ), a leading company ... commercialize novel flavor ingredients for the food, beverage, and ... second quarter 2015. "Moving into the ... achieve our commercial and financial goals," stated John Poyhonen, ... our last quarterly earnings report, our two partners have ...
(Date:7/30/2015)... 2015 Ascendis Pharma A/S (Nasdaq: ... innovative TransCon technology to address significant unmet medical ... six-month Phase 2 study to evaluate the safety ... 53 treatment-naïve, pre-pubertal children with growth hormone deficiency, ... with the top-line results from our Phase 2 ...
Breaking Biology Technology:Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... ... Datafarm for production of Hybrid eCTD submissions to Health Canada. Datafarm’s announcement comes on ... that, effective immediately, sponsor companies may submit Hybrid eCTD regulatory submissions for New Drug ... ...
... 5, 2009 Complete Genomics, a third-generation human genome ... the journal Science describing its proprietary DNA ... complete human genomes. The consumables cost for these three ... from $8,005 for 87x coverage to $1,726 for 45x ...
... (TSX, FSE: "HBP" / Pink Sheets: HXBPF) today announced that ... Merriman Curhan Ford,s 6th annual Investor Summit on November 10, ... York City. Mr. Docherty will provide an overview of ... Alpha-2b. The slide show portion of the presentation will ...
Cached Biology Technology:Datafarm Responds to Health Canada's Announcement of Hybrid eCTD Submission Procedural Simplification 2Complete Genomics publishes in Science on low-cost sequencing of 3 human genomes 2Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 2Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 3
(Date:7/13/2015)... SAN JOSE, Calif. , July 13, 2015 ... the leading developer of human interface solutions, today ... second generation touch and display driver integration (TDDI) ... solution is the first to combine Synaptics , ... expertise with proven display driver technology developed in ...
(Date:7/9/2015)... July 07, 2015 ... addition of the "Biometrics for Banking; Market ... report to their offering. The ... to this growth and the forecast is that ... revenue for companies involved in delivering biometric systems ...
(Date:7/8/2015)... Summary Pancreatic cancer is the 12th ... with a mortality rate of 10.9 deaths per 100,000 ... patients has highlighted a significant need for new and ... by the current market. A highly active pancreatic ... molecule types and mechanisms of action, which provides a ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... Starting in May 2009, Springer will publish the ... of the Japanese Society of Biorheology. This ... physiologists and materials scientists to exchange and discuss ... Journal of Biorheology covers the science and ...
... NEW YORK (April 23, 2009) The Wildlife Conservation ... reefs off East Africa are unusually resilient to climate ... of geophysical factors. WCS announced the results of ... which is meeting this week in Phuket, Thailand. ...
... Marine scientists say they are astonished at the spectacular recovery ... Park from a devastating coral bleaching event in 2006. ... bleaching in the Keppel Islands, in the southern part of ... a single species of seaweed an event that can ...
Cached Biology News:Springer and Japanese Society of Biorheology to work together 2'Super reefs' fend off climate change, study says 2Reef boom beats doom 2
Chicken Anti-Human DNA-directed RNA Polymerase II 7.6 Kd Polypeptide (POLR2L Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
The BD CBA Human Apoptosis Kit can be used to quantitatively measure,cleaved PARP, Bcl-2, and active Caspase-3 protein levels in a single sample. The,Kit performance has been optimized for analysis o...
... proteases/caspases initiates apoptosis in mammalian cells. ... provides a simple and convenient means for ... in intact cells. The assay utilizes ... linked to rhodamine 110 (D2R), a reported ...
The PROTEAN II slab gel casting stand is a component of the PROTEAN II XL and xi casting apparatus. It is supplied with gaskets....
Biology Products: